This identified PD-L2 and CD86 (ligands to classical CRs) but also CD155 and CD112 (ligands to alternative CRs) as potential prognostic biomarkers for the survival of AML patients. This evidence concerns the gene PDCD1LG2 and acute myeloid leukemia.